Steinhorn S C, Kopecky K J, Myers M H, Ball C
J Natl Cancer Inst. 1983 Apr;70(4):629-34.
The characteristics of colon cancer tumors diagnosed in patients seen at hospitals participating in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program and at Comprehensive Cancer Centers (CCC's) belonging to the Centralized Cancer Patient Data System (CCPDS) are compared. There were identified among cases diagnosed between July 1, 1977 and December 31, 1978, the first 18 months of registration for the CCPDS centers. A higher proportion of CCPDS colon tumors were diagnosed in black patients, 15.4% versus 6.8% for SEER, reflecting the urban location of many CCC's. The CCPDS has proportionally fewer patients aged 75 years or older, and a median age of 67.5 years versus 70 years for the SEER cases. Although surgery alone was the major form of therapy for both CCPDS and SEER patients with colon tumors, higher percentages of CCPDS patients than SEER patients were treated by chemotherapy alone or by modalities other than surgery, chemotherapy, and radiotherapy, particularly those with later stages of the disease. Few disagreements existed between the 2 groups in distribution by segment of the colon, stage, and histologic type. Few differences were found that would render invalid future comparative analyses of patient survival between the two data systems once adequate follow-up information is available. Such an evaluation may be a valuable instrument in measuring whether improvements in cancer patient management being developed at CCC's are, in fact, "filtering down" to the general series of colon cancer patients.
对参与美国国立癌症研究所监测、流行病学和最终结果(SEER)计划的医院以及属于集中癌症患者数据系统(CCPDS)的综合癌症中心(CCC)中确诊的结肠癌肿瘤特征进行了比较。在1977年7月1日至1978年12月31日(CCPDS中心注册的前18个月)期间确诊的病例中进行了识别。CCPDS结肠癌肿瘤在黑人患者中的诊断比例更高,分别为15.4%和6.8%,这反映了许多CCC位于城市地区。CCPDS中75岁及以上的患者比例相对较少,中位年龄为67.5岁,而SEER病例为70岁。尽管单纯手术是CCPDS和SEER结肠癌肿瘤患者的主要治疗方式,但CCPDS患者中仅接受化疗或接受手术、化疗和放疗以外治疗方式的比例高于SEER患者,尤其是疾病晚期患者。两组在结肠癌段分布、分期和组织学类型方面的分歧很少。一旦有足够的随访信息,很少发现会使两个数据系统未来患者生存比较分析无效的差异。这样的评估可能是衡量CCC正在开展的癌症患者管理改进是否实际上“向下渗透”到一般结肠癌患者系列中的一个有价值的工具。